Though the number of EGFR amplified grade II gliomas was small (n = 6), it's worthwhile to note that this small subset of grade II tumors exhibited worse prognosis than EGFR non-amplified grade III gliomas (p = 0.006). The gene discussed is EGFR; the disease is glioma.